Avery Schumer
All posts from Avery Schumer
Avery Schumer in Sector Report,

Could Relypsa Be The Next Big Pharma Buyout Target?

Relypsa Inc  shares are down 38 percent year-to-date, while shares of ZS Pharma Inc  are up 14 percent over the same period.

Citi’s Yigal Nochomovitz maintained a Buy rating on both companies, with price targets of $45 for Relypsa and of $82 for ZS Pharma.

The proposed indication of ZS Pharma validates the bull thesis on the hyperkalemia market and the potential of Relypsa’s Veltassa, Nochomovitz stated.